comprehensive -WSS

comprehensive

author：comprehensive 2025-08-12 13:36:31 - browse：9

Adam's take main illustration — Molly Ferguson/STAT

This week, an encouraging turnaround for Ocular Therapeutix, a chat with Alnylam’s CEO defending changes to the HELIOS-B study and talking up its hypertension treatment, and quick takes on Amylyx and obesity stocks.

A Worst CEO gets some much-needed help

For most of last year, Ocular Therapeutix CEO Antony Mattessich promised shareholders that he was close to nailing down a lucrative pharma partnership that would pay for late-stage clinical trials of the company’s treatments for degenerative eye diseases. The deal never happened. I heard from many Ocular investors who were frustrated and angry about Mattesich’s poor job performance. He ended up earning a spot last year on my worst biopharma CEO list. It was an easy pick.

On Thursday, Ocular announced a meaningful “leadership update.” Mattessich is still the CEO, but let’s just say the company’s board decided to surround him with new executives and retinal experts with proven track records of getting stuff done.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Shifting the focus from loneliness to social health

leisure time

WSS

Woman returns to dialysis after doctors remove transplanted pig kidney

Cord blood banking comes at a high cost to babies

Change Healthcare can notify patients about the breach, HHS says

BMI, flaws aside, is found to be useful estimate of body fat in youth

BMI, flaws aside, is found to be useful estimate of body fat in youth

BMI, flaws aside, is found to be useful estimate of body fat in youth

entertainment

comprehensive

A Worst CEO gets some much-needed help

explore

Duchenne breakthrough therapy leaves behind pioneering families

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Novavax promises a turnaround & Lilly roils the obesity market

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Supreme Court strikes down use of affirmative action

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Apple is now the first public company to be valued at $3 trillion

How to increase colonoscopy rates? Looks like an AI can help

Medicare proposal to cover medical devices draws a mixed reaction

Innovation in antibiotics is ailing. 'Brain drain' may kill it

explore

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

FDA's Pazdur wants cancer trials to range beyond China alone

NIH documents show early flaws of $1.6 billion long Covid program

Intellia reports positive results for its CRISPR

Shifting the focus from loneliness to social health

Let's speed up science by embracing open access publishing

leisure time

hotspot

leisure time

hotspot